The BRAIN Foundation - Potential of MEF2 Transcriptional Activator Therapy for ASD Phenotypes - STUART LIPTON, MD, PhD Hannah and Eugene Step Chair; Professor; Co-director, Neuroscience Translational Center Department of Molecular Medicine,
NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models | Molecular Psychiatry
Potential New Autism Drug Shows Promise in Mice | Lab Manager
NitroSynapsin inhibits spontaneous calcium activity and 0.2–1 Hz events... | Download Scientific Diagram
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
IJMS | Free Full-Text | Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases | HTML
On the spectrum of hope - Scripps Research Magazine
Modified Alzheimer's drug may treat some forms of autism | Spectrum | Autism Research News
PDF) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models | Request PDF
New Autism Drug Shows Promise in Preclinical Study
New Autism Drug Shows Promise in Preclinical Study
On the spectrum of hope - Scripps Research Magazine
Human Neurons from Ctrl- and AD-Patient-Derived iPSCs Are Resistant to... | Download Scientific Diagram
Aberrant gliogenesis and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids | bioRxiv
A drug candidate holds promise in treating autism - Cusabio
NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model - ScienceDirect
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model - ScienceDirect
Mouse Model Demonstrates Potential of New Autism Drug | Technology Networks
WO2019028025A1 - Methods and compositions for treating neurological conditions - Google Patents
